Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10335-10349

  Singh, Chandra K ^a   Kaur, Satwinderjeet ^a   George, Jasmine ^a   Nihal, Minakshi ^a   Hahn, Molly C Pellitteri ^a   Scarlett, Cameron O ^a   Ahmad, Nihal ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemoprevention; DUSP4; Pancreatic cancer; Quantitative proteomics; Sanguinarine

Indexed keywords

CASPASE 7; COP9 SIGNALOSOME; CULLIN; CULLIN 5; CYCLINE; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; GPS1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 33; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SANGUINARINE; UNCLASSIFIED DRUG; BENZOPHENANTHRIDINE DERIVATIVE; ISOQUINOLINE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE ONTOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SWISS-PROT; TANDEM MASS SPECTROMETRY; UPREGULATION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

BENZOPHENANTHRIDINES; CELL LINE, TUMOR; HUMANS; IMMUNOBLOTTING; ISOQUINOLINES; PANCREATIC NEOPLASMS; PROTEOMICS;

EID: 84929589862     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3231     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014; 64:9-29.
2. Mackraj I, Govender T, Gathiram P. Sanguinarine. Cardiovasc Ther. 2008; 26:75-83.
3. Burgeiro A, Bento AC, Gajate C, Oliveira PJ, Mollinedo F. Rapid human melanoma cell death induced by sanguinarine through oxidative stress. Eur J Pharmacol. 2013; 705:109-118.
4. Xu JY, Meng QH, Chong Y, Jiao Y, Zhao L, Rosen EM, Fan S. Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration. Mol Clin Oncol. 2013; 1:331-336.
5. Park SY, Jin ML, Kim YH, Lee SJ, Park G. Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. Oncol Rep. 2014; 31:497-504.
6. Han MH, Kim GY, Yoo YH, Choi YH. Sanguinarine induces apoptosis in human colorectal cancer HCT-116 cells through ROS-mediated Egr-1 activation and mitochondrial dysfunction. Toxicol Lett. 2013; 220:157-166.
7. Niu X, Fan T, Li W, Huang H, Zhang Y, Xing W. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice. Toxicol Appl Pharmacol. 2013; 267:256-265.
8. Han MH, Park C, Jin CY, Kim GY, Chang YC, Moon SK, Kim WJ, Choi YH. Apoptosis induction of human bladder cancer cells by sanguinarine through reactive oxygen species-mediated up-regulation of early growth response gene-1. PLoS One. 2013; 8:e63425.
9. Ahsan H, Reagan-Shaw S, Breur J, Ahmad N. Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins. Cancer Lett. 2007; 249:198-208.
10. Ahmad N, Gupta S, Husain MM, Heiskanen KM, Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin Cancer Res. 2000; 6:1524-1528.
11. Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H, Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol Cancer Ther. 2004; 3:933-940.
12. Malikova J, Zdarilova A, Hlobilkova A. Effects of sanguinarine and chelerythrine on the cell cycle and apoptosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006; 150:5-12.
13. Eun JP, Koh GY. Suppression of angiogenesis by the plant alkaloid, sanguinarine. Biochem Biophys Res Commun. 2004; 317:618-624.
14. Weerasinghe P, Buja LM. Oncosis: an important nonapoptotic mode of cell death. Exp Mol Pathol. 2012; 93:302-308.
15. Ji X, Sun H, Zhou H, Xiang J, Tang Y, Zhao C. The interaction of telomeric DNA and C-myc G-quadruplex with 11 natural alkaloids. Nucleic Acid Ther. 2012; 22:127-136.
16. Zhu W, Smith JW, Huang CM. Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol. 2010; 2010:840518.
17. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010; 39:425-435.
18. Nilsson T, Mann M, Aebersold R, Yates JR 3rd, Bairoch A, Bergeron JJ. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods. 2010; 7:681-685.
19. Vlachojannis C, Magora F, Chrubasik S. Rise and fall of oral health products with Canadian bloodroot extract. Phytother Res. 2012; 26:1423-1426.
20. Cagnol S, Rivard N. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/ MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene. 2013; 32:564-576.
21. Fay MJ, Longo KA, Karathanasis GA, Shope DM, Mandernach CJ, Leong JR, Hicks A, Pherson K, Husain A. Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues. Mol Cancer. 2003; 2:40.
22. Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 2012; 60:514-521.
23. Spain BH, Bowdish KS, Pacal AR, Staub SF, Koo D, Chang CY, Xie W, Colicelli J. Two human cDNAs, including a homolog of Arabidopsis FUS6 (COP11), suppress G-protein- and mitogen-activated protein kinase-mediated signal transduction in yeast and mammalian cells. Mol Cell Biol. 1996; 16:6698-6706.
24. Guan KL, Butch E. Isolation and characterization of a novel dual specific phosphatase, HVH2, which selectively dephosphorylates the mitogen-activated protein kinase. J Biol Chem. 1995; 270:7197-7203.
25. Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov. 2007; 6:391-403.
26. De Stefano I, Raspaglio G, Zannoni GF, Travaglia D, Prisco MG, Mosca M, Ferlini C, Scambia G, Gallo D. Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma. Biochem Pharmacol. 2009; 78:1374-1381.
27. Niu X, Fan T, Li W, Xing W, Huang H. The anti-inflammatory effects of sanguinarine and its modulation of inflammatory mediators from peritoneal macrophages. Eur J Pharmacol. 2012; 689:262-269.
28. Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Okugawa Y, Shimura T, Hiro J, Uchida K, Mohri Y, Kusunoki M. Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer. Med Oncol. 2013; 30:620.
29. Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gomez H, Cook RS, Arteaga CL. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013; 73:6346-6358.
30. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, Wiestler OD, Reifenberger G, Pietsch T, Waha A. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res. 2010; 70:1689-1699.
31. Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer. 2003; 2:12.
32. Shen WH, Wang J, Wu J, Zhurkin VB, Yin Y. Mitogenactivated protein kinase phosphatase 2: a novel transcription target of p53 in apoptosis. Cancer Res. 2006; 66:6033-6039.
33. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321:1801-1806.
34. Kosina P, Walterova D, Ulrichova J, Lichnovsky V, Stiborova M, Rydlova H, Vicar J, Krecman V, Brabec MJ, Simanek V. Sanguinarine and chelerythrine: assessment of safety on pigs in ninety days feeding experiment. Food Chem Toxicol. 2004; 42:85-91.
35. Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer. 2010; 1:283-292.
36. Thomas S, Bonchev D. A survey of current software for network analysis in molecular biology. Hum Genomics. 2010; 4:353-360.
37. Wang X, Spandidos A, Wang H, Seed B. PrimerBank: a PCR primer database for quantitative gene expression analysis, update. Nucleic Acids Res. 2012; 40:D1144-1149.
38. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM, Suo Z. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One. 2011; 6:e29170.